Equities analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report ($0.91) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is ($0.88) and the lowest is ($0.94). Acorda Therapeutics reported earnings of $0.10 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,010%. The firm is expected to issue its next earnings results on Wednesday, October 30th.
On average, analysts expect that Acorda Therapeutics will report full-year earnings of ($2.97) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($3.11) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.53. Acorda Therapeutics had a negative net margin of 25.94% and a negative return on equity of 6.18%. The firm had revenue of $50.05 million for the quarter, compared to analyst estimates of $28.83 million. During the same period last year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was down 67.4% compared to the same quarter last year.
A number of analysts recently issued reports on ACOR shares. JPMorgan Chase & Co. set a $7.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Friday, August 2nd. Stifel Nicolaus reduced their price objective on shares of Acorda Therapeutics from $12.00 to $7.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Wedbush reduced their price objective on shares of Acorda Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. HC Wainwright lowered shares of Acorda Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $31.00 to $6.00 in a research report on Wednesday, August 14th. Finally, ValuEngine upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 2nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $12.73.
Shares of ACOR traded down $0.18 during trading hours on Tuesday, reaching $3.39. 2,344,500 shares of the stock traded hands, compared to its average volume of 1,127,895. The company has a current ratio of 3.81, a quick ratio of 3.52 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $3.43 and a 200 day simple moving average of $8.66. Acorda Therapeutics has a 52 week low of $2.27 and a 52 week high of $21.63. The company has a market cap of $169.83 million, a price-to-earnings ratio of 1.86 and a beta of 1.26.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in Acorda Therapeutics during the 2nd quarter valued at $8,647,000. Renaissance Technologies LLC increased its position in Acorda Therapeutics by 13.6% during the 2nd quarter. Renaissance Technologies LLC now owns 4,558,000 shares of the biopharmaceutical company’s stock valued at $34,960,000 after purchasing an additional 546,700 shares during the period. Acadian Asset Management LLC increased its position in Acorda Therapeutics by 57.9% during the 1st quarter. Acadian Asset Management LLC now owns 923,041 shares of the biopharmaceutical company’s stock valued at $12,268,000 after purchasing an additional 338,294 shares during the period. AXA increased its position in Acorda Therapeutics by 898.8% during the 2nd quarter. AXA now owns 240,700 shares of the biopharmaceutical company’s stock valued at $1,846,000 after purchasing an additional 216,600 shares during the period. Finally, Diamond Hill Capital Management Inc. increased its position in Acorda Therapeutics by 77.9% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 489,329 shares of the biopharmaceutical company’s stock valued at $3,753,000 after purchasing an additional 214,227 shares during the period.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.